Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways...